Page last updated: 2024-10-27

flurbiprofen and Neoplasms

flurbiprofen has been researched along with Neoplasms in 6 studies

Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"To compare the treatment effect reducing cancer-related multiple breakthrough pain (BTP) between immediate release morphine sulfate (IRMS) and flurbiprofen axetil."7.79Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study. ( Cheng, X; Hao, J; Shao, Y; Wang, K; Yan, Z, 2013)
"To compare the treatment effect reducing cancer-related multiple breakthrough pain (BTP) between immediate release morphine sulfate (IRMS) and flurbiprofen axetil."3.79Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study. ( Cheng, X; Hao, J; Shao, Y; Wang, K; Yan, Z, 2013)
"A total of 120 cancer patients was randomly divided into two groups, 60 patients took orally morphine sulfate sustained-release tablets in group A, and another 60 patients receiving the combination treatment of intravenous flurbiprofen axetil and opioid drugs in group B."2.79Intravenous flurbiprofen axetil enhances analgesic effect of opioids in patients with refractory cancer pain by increasing plasma β-endorphin. ( Gao, JF; Ou, WL; Rao, ZG; Wang, J; Wang, ZG; Wu, TT; Yang, B; Yao, GQ; Zhang, BC, 2014)
"Alimentary mucositis is a significant complication of cancer therapy, with important clinical and economic implications."2.43Anti-inflammatory agents in the management of alimentary mucositis. ( Bensadoun, RJ; Keefe, D; Lalla, RV; Schubert, MM, 2006)
"Thirty-seven cases of cancer patients who had bad effect from anaesthetic drugs were received administration of intravenous flurbiprofen axetil with dose of 50 mg/5 ml/day."1.35Intravenous flurbiprofen axetil can increase analgesic effect in refractory cancer pain. ( Chen, Z; Du, Y; Gu, K; Hao, J; Ning, J; Pan, Y; Sun, G; Wu, H, 2009)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L1
Hitosugi, T1
Zhang, L1
Zhang, S1
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y1
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J1
Şenel, B1
Öztürk, AA1
Wu, TT1
Wang, ZG1
Ou, WL1
Wang, J1
Yao, GQ1
Yang, B1
Rao, ZG1
Gao, JF1
Zhang, BC1
Wu, H1
Chen, Z1
Sun, G1
Gu, K1
Pan, Y1
Hao, J2
Du, Y1
Ning, J1
Wang, K1
Shao, Y1
Cheng, X1
Yan, Z1
Lalla, RV1
Schubert, MM1
Bensadoun, RJ1
Keefe, D1

Reviews

2 reviews available for flurbiprofen and Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015
Anti-inflammatory agents in the management of alimentary mucositis.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Allopurinol; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antineoplastic Agents; Benzydamin

2006

Trials

1 trial available for flurbiprofen and Neoplasms

ArticleYear
Intravenous flurbiprofen axetil enhances analgesic effect of opioids in patients with refractory cancer pain by increasing plasma β-endorphin.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:24

    Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; beta-Endorphin; Drug Synergism; Drug Th

2014

Other Studies

3 other studies available for flurbiprofen and Neoplasms

ArticleYear
New approaches to tumor therapy with siRNA-decorated and chitosan-modified PLGA nanoparticles.
    Drug development and industrial pharmacy, 2019, Volume: 45, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cancer Pain; Cell Line, Tumor; Cell Survival; Chitosan; C

2019
Intravenous flurbiprofen axetil can increase analgesic effect in refractory cancer pain.
    Journal of experimental & clinical cancer research : CR, 2009, Mar-07, Volume: 28

    Topics: Analgesia; Female; Flurbiprofen; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Pain

2009
Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study.
    Journal of palliative medicine, 2013, Volume: 16, Issue:2

    Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Breakthrough Pain; Case-Control Studies

2013